These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30361185)

  • 1. Lacosamide for SCN2A-related intractable neonatal and infantile seizures.
    Flor-Hirsch H; Heyman E; Livneh A; Reish O; Watemberg N; Litmanovits I; Ben Sason Lilli A; Lev D; Lerman Sagie T; Bassan H
    Epileptic Disord; 2018 Oct; 20(5):440-446. PubMed ID: 30361185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal SCN2A encephalopathy: A peculiar recognizable electroclinical sequence.
    Melikishvili G; Dulac O; Gataullina S
    Epilepsy Behav; 2020 Oct; 111():107187. PubMed ID: 32603808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine.
    Foster LA; Johnson MR; MacDonald JT; Karachunski PI; Henry TR; Nascene DR; Moran BP; Raymond GV
    Pediatr Neurol; 2017 Jan; 66():108-111. PubMed ID: 27867041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phenotype and treatment of SCN2A-related developmental and epileptic encephalopathy.
    Kim HJ; Yang D; Kim SH; Kim B; Kim HD; Lee JS; Choi JR; Lee ST; Kang HC
    Epileptic Disord; 2020 Oct; 22(5):563-570. PubMed ID: 33000761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm responsive to a ketogenic diet.
    Su DJ; Lu JF; Lin LJ; Liang JS; Hung KL
    Brain Dev; 2018 Sep; 40(8):724-727. PubMed ID: 29625812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
    Wolff M; Johannesen KM; Hedrich UBS; Masnada S; Rubboli G; Gardella E; Lesca G; Ville D; Milh M; Villard L; Afenjar A; Chantot-Bastaraud S; Mignot C; Lardennois C; Nava C; Schwarz N; Gérard M; Perrin L; Doummar D; Auvin S; Miranda MJ; Hempel M; Brilstra E; Knoers N; Verbeek N; van Kempen M; Braun KP; Mancini G; Biskup S; Hörtnagel K; Döcker M; Bast T; Loddenkemper T; Wong-Kisiel L; Baumeister FM; Fazeli W; Striano P; Dilena R; Fontana E; Zara F; Kurlemann G; Klepper J; Thoene JG; Arndt DH; Deconinck N; Schmitt-Mechelke T; Maier O; Muhle H; Wical B; Finetti C; Brückner R; Pietz J; Golla G; Jillella D; Linnet KM; Charles P; Moog U; Õiglane-Shlik E; Mantovani JF; Park K; Deprez M; Lederer D; Mary S; Scalais E; Selim L; Van Coster R; Lagae L; Nikanorova M; Hjalgrim H; Korenke GC; Trivisano M; Specchio N; Ceulemans B; Dorn T; Helbig KL; Hardies K; Stamberger H; de Jonghe P; Weckhuysen S; Lemke JR; Krägeloh-Mann I; Helbig I; Kluger G; Lerche H; Møller RS
    Brain; 2017 May; 140(5):1316-1336. PubMed ID: 28379373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketogenic diet as a successful early treatment modality for SCN2A mutation.
    Turkdogan D; Thomas G; Demirel B
    Brain Dev; 2019 Apr; 41(4):389-391. PubMed ID: 30415926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phenotype study of SCN2A gene related epilepsy].
    Zeng Q; Zhang YH; Yang XL; Zhang J; Liu AJ; Liu XY; Jiang YW; Wu XR
    Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):518-523. PubMed ID: 29996185
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations in SCN3A cause early infantile epileptic encephalopathy.
    Zaman T; Helbig I; Božović IB; DeBrosse SD; Bergqvist AC; Wallis K; Medne L; Maver A; Peterlin B; Helbig KL; Zhang X; Goldberg EM
    Ann Neurol; 2018 Apr; 83(4):703-717. PubMed ID: 29466837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures.
    Howell KB; McMahon JM; Carvill GL; Tambunan D; Mackay MT; Rodriguez-Casero V; Webster R; Clark D; Freeman JL; Calvert S; Olson HE; Mandelstam S; Poduri A; Mefford HC; Harvey AS; Scheffer IE
    Neurology; 2015 Sep; 85(11):958-66. PubMed ID: 26291284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy.
    Dilena R; Striano P; Gennaro E; Bassi L; Olivotto S; Tadini L; Mosca F; Barbieri S; Zara F; Fumagalli M
    Brain Dev; 2017 Apr; 39(4):345-348. PubMed ID: 27876397
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yang XR; Ginjupalli VKM; Theriault O; Poulin H; Appendino JP; Au PYB; Chahine M
    J Neurophysiol; 2022 May; 127(5):1388-1397. PubMed ID: 35417276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a personalized phenytoin dosing approach to manage difficult to control seizures in an infant with a SCN2A mutation.
    Welzel T; Ziesenitz VC; Waldvogel S; Scheidegger S; Weber P; van den Anker JN; Gotta V
    Eur J Clin Pharmacol; 2019 May; 75(5):737-739. PubMed ID: 30643928
    [No Abstract]   [Full Text] [Related]  

  • 14. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice.
    Brunklaus A; Du J; Steckler F; Ghanty II; Johannesen KM; Fenger CD; Schorge S; Baez-Nieto D; Wang HR; Allen A; Pan JQ; Lerche H; Heyne H; Symonds JD; Zuberi SM; Sanders S; Sheidley BR; Craiu D; Olson HE; Weckhuysen S; DeJonge P; Helbig I; Van Esch H; Busa T; Milh M; Isidor B; Depienne C; Poduri A; Campbell AJ; Dimidschstein J; Møller RS; Lal D
    Epilepsia; 2020 Mar; 61(3):387-399. PubMed ID: 32090326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation in the neonatal isoform of SCN2A causes neonatal-onset epilepsy.
    Penkl A; Reunert J; Debus OM; Homann A; Och U; Rust S; Marquardt T
    Am J Med Genet A; 2022 Mar; 188(3):941-947. PubMed ID: 34874093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the efficacy and influencing factors of sodium channel blockers in the treatment of focal epilepsy in infants under 6 months of age].
    Ma YP; Deng J; Fu ZR; Chen CH; Wang XH; Wang X; Weng JW; Shen YH
    Zhonghua Er Ke Za Zhi; 2023 Nov; 61(11):983-988. PubMed ID: 37899337
    [No Abstract]   [Full Text] [Related]  

  • 17. Lacosamide in patients with intellectual disability and refractory epilepsy.
    Kleist A; Kerling F; Hamer H; Winterholler M
    Acta Neurol Belg; 2019 Sep; 119(3):423-430. PubMed ID: 30840220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirming an expanded spectrum of SCN2A mutations: a case series.
    Matalon D; Goldberg E; Medne L; Marsh ED
    Epileptic Disord; 2014 Mar; 16(1):13-8. PubMed ID: 24659627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia.
    Schwarz N; Hahn A; Bast T; Müller S; Löffler H; Maljevic S; Gaily E; Prehl I; Biskup S; Joensuu T; Lehesjoki AE; Neubauer BA; Lerche H; Hedrich UBS
    J Neurol; 2016 Feb; 263(2):334-343. PubMed ID: 26645390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant.
    Que Z; Olivero-Acosta MI; Zhang J; Eaton M; Tukker AM; Chen X; Wu J; Xie J; Xiao T; Wettschurack K; Yunis L; Shafer JM; Schaber JA; Rochet JC; Bowman AB; Yuan C; Huang Z; Hu CD; Trader DJ; Skarnes WC; Yang Y
    J Neurosci; 2021 Dec; 41(49):10194-10208. PubMed ID: 34716231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.